As TKIs effectively lead to amyloid clearance by ubiquitination of Parkin and activation of Parkin–beclin-1 interaction (31, 32), the prescription of TKIs may be associated with a lower risk of dementia and PD. This evidence concerns the gene BECN1 and dementia.